Hutchmed China shares rise as tumour treatment trial begins
4th Mar 2026 12:08
(Alliance News) - Hutchmed China Ltd on Wednesday said it had launched a Phase I/IIa clinical trial of its cancer treatment HMPL-A580. Read More
| Price | 203.00p on 05-03-2026 at 09:07:28 |
|---|---|
| Change | -3.00p -1.46% |
| Buy | 208.00p |
| Sell | 196.50p |
| Last Trade: | Buy 15.00 at 203.00p |
| Day's Volume: | 696 |
| Last Close: | 206.00p |
| Open: | 210.00p |
| ISIN: | KYG4672N1198 |
| Day's Range | 203.00p - 210.00p |
| 52wk Range: | 187.50p - 292.00p |
| Market Capitalisation: | £1.74b |
| VWAP: | 203.05101p |
| Shares in Issue: | 859.52m |
Sector: Medicine and Biotech
Listed In: FTSE AIM 100, FTSE AIM All-Share,
Hutchmed (HCM) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Buy* | 15 | 203.00p | SI Trade |
09:07:05 - 05-Mar-26 |
| Buy* | 15 | 204.00p | SI Trade |
09:07:05 - 05-Mar-26 |
| Buy* | 15 | 203.00p | Automatic Execution |
09:07:05 - 05-Mar-26 |
| Buy* | 15 | 203.00p | Automatic Execution |
09:07:05 - 05-Mar-26 |
| Buy* | 15 | 204.00p | SI Trade |
08:54:15 - 05-Mar-26 |
| Buy* | 15 | 204.00p | Automatic Execution |
08:54:15 - 05-Mar-26 |
| Buy* | 15 | 204.00p | Automatic Execution |
08:53:43 - 05-Mar-26 |
| Buy* | 15 | 204.00p | SI Trade |
08:53:43 - 05-Mar-26 |
| Buy* | 15 | 204.00p | SI Trade |
08:53:17 - 05-Mar-26 |
| Buy* | 15 | 204.00p | Automatic Execution |
08:53:17 - 05-Mar-26 |
Hutchmed (HCM) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 4th Mar 2026 8:30 am | RNS-R | HUTCHMED Initiates Global Trial of ATTC Candidate |
| 6th Feb 2026 8:30 am | RNS | HUTCHMED to Announce 2025 Final Results |
| 14th Jan 2026 7:00 am | RNS-R | Publication of Phase III Results in The Lancet |
| 7th Jan 2026 7:00 am | RNS-R | Positive Topline Results of Phase III Trial |
| 5th Jan 2026 7:00 am | RNS-R | Surufatinib + Camrelizumab PDAC Phase 3 initiation |
| 31st Dec 2025 7:00 am | RNS | Total Voting Rights |
| 31st Dec 2025 7:00 am | RNS | Total Voting Rights |
| 30th Dec 2025 10:00 am | RNS-R | China NDA Acceptance-Savolitinib in Gastric Cancer |
| 30th Dec 2025 10:00 am | RNS-R | China NDA Acceptance-Savolitinib in Gastric Cancer |
| 29th Dec 2025 8:30 am | RNS | Blocklisting Six Monthly Return |